| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs
|
Park, Ji Soo
|
|
2019
|
134 |
C |
p. 46-51
|
artikel
|
| 2 |
Characterization of lung adenocarcinoma with a cribriform component reveals its association with spread through air spaces and poor outcomes
|
Ding, Qifeng
|
|
2019
|
134 |
C |
p. 238-244
|
artikel
|
| 3 |
Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer
|
Manjunath, Yariswamy
|
|
2019
|
134 |
C |
p. 147-150
|
artikel
|
| 4 |
Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer
|
Zhang, Bin
|
|
2019
|
134 |
C |
p. 108-116
|
artikel
|
| 5 |
Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer
|
Hyun, Myung Han
|
|
2019
|
134 |
C |
p. 158-166
|
artikel
|
| 6 |
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
|
Zugazagoitia, Jon
|
|
2019
|
134 |
C |
p. 72-78
|
artikel
|
| 7 |
Contents
|
|
|
2019
|
134 |
C |
p. v-vii
|
artikel
|
| 8 |
Corrigendum to “Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos” [Lung Cancer, 131 (May) (2019) 23–30]
|
Maisonneuve, Patrick
|
|
2019
|
134 |
C |
p. 279
|
artikel
|
| 9 |
CT screening for lung cancer: Are we ready to implement in Europe?
|
Balata, Haval
|
|
2019
|
134 |
C |
p. 25-33
|
artikel
|
| 10 |
Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study
|
Lang, David
|
|
2019
|
134 |
C |
p. 59-65
|
artikel
|
| 11 |
Editorial Board
|
|
|
2019
|
134 |
C |
p. iii
|
artikel
|
| 12 |
Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer
|
Hayashi, Hideki
|
|
2019
|
134 |
C |
p. 1-6
|
artikel
|
| 13 |
Endobronchial and surgical treatment of pulmonary carcinoid tumors: A systematic literature review
|
Reuling, E.M.B.P.
|
|
2019
|
134 |
C |
p. 85-95
|
artikel
|
| 14 |
Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme
|
Ghimire, Bhagabati
|
|
2019
|
134 |
C |
p. 66-71
|
artikel
|
| 15 |
Evaluation of maximum standardized uptake value at fluorine-18 fluorodeoxyglucose positron emission tomography as a complementary T factor in the eighth edition of lung cancer stage classification
|
Kim, Hyungjin
|
|
2019
|
134 |
C |
p. 151-157
|
artikel
|
| 16 |
Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study
|
Gibson, Amanda J.W.
|
|
2019
|
134 |
C |
p. 141-146
|
artikel
|
| 17 |
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial
|
Capelletto, Enrica
|
|
2019
|
134 |
C |
p. 210-217
|
artikel
|
| 18 |
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light
|
Ackermann, Christoph Jakob
|
|
2019
|
134 |
C |
p. 245-253
|
artikel
|
| 19 |
Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer
|
Kasahara, Norimitsu
|
|
2019
|
134 |
C |
p. 180-186
|
artikel
|
| 20 |
Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis
|
Bousema, Jelle E.
|
|
2019
|
134 |
C |
p. 52-58
|
artikel
|
| 21 |
Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites
|
Yoshimura, Katsuhiro
|
|
2019
|
134 |
C |
p. 202-209
|
artikel
|
| 22 |
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
|
Haragan, Alexander
|
|
2019
|
134 |
C |
p. 79-84
|
artikel
|
| 23 |
Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer
|
Owen, Dwight H.
|
|
2019
|
134 |
C |
p. 167-173
|
artikel
|
| 24 |
Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients
|
Francaviglia, Ilaria
|
|
2019
|
134 |
C |
p. 225-232
|
artikel
|
| 25 |
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
|
Dafni, Urania
|
|
2019
|
134 |
C |
p. 127-140
|
artikel
|
| 26 |
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer
|
Melosky, Barbara
|
|
2019
|
134 |
C |
p. 259-267
|
artikel
|
| 27 |
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer
|
Hellyer, Jessica A.
|
|
2019
|
134 |
C |
p. 42-45
|
artikel
|
| 28 |
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial
|
Santo, Antonio
|
|
2019
|
134 |
C |
p. 121-126
|
artikel
|
| 29 |
Misclassification of the actual causes of death and its impact on analysis: A case study in non-small cell lung cancer
|
Tan, Kay See
|
|
2019
|
134 |
C |
p. 16-24
|
artikel
|
| 30 |
Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial
|
Fujimoto, Daichi
|
|
2019
|
134 |
C |
p. 274-278
|
artikel
|
| 31 |
Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens
|
Vannitamby, Amanda
|
|
2019
|
134 |
C |
p. 233-237
|
artikel
|
| 32 |
Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells
|
Nakamura, Hiroshi
|
|
2019
|
134 |
C |
p. 100-107
|
artikel
|
| 33 |
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
|
Park, Sehhoon
|
|
2019
|
134 |
C |
p. 7-15
|
artikel
|
| 34 |
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study
|
Dietel, M.
|
|
2019
|
134 |
C |
p. 174-179
|
artikel
|
| 35 |
Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA
|
Supplee, Julianna G.
|
|
2019
|
134 |
C |
p. 96-99
|
artikel
|
| 36 |
Small cell lung cancer elevates procalcitonin levels in the absence of infection
|
Pardo-Cabello, Alfredo Jose
|
|
2019
|
134 |
C |
p. 272-273
|
artikel
|
| 37 |
The expanding role of endobronchial ultrasound in patients with centrally located intrapulmonary tumors
|
Kuijvenhoven, J.C.
|
|
2019
|
134 |
C |
p. 194-201
|
artikel
|
| 38 |
The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer
|
Liu, Zhichao
|
|
2019
|
134 |
C |
p. 218-224
|
artikel
|
| 39 |
The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study
|
Ding, P.N.
|
|
2019
|
134 |
C |
p. 187-193
|
artikel
|
| 40 |
Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib
|
Coleman, Niamh
|
|
2019
|
134 |
C |
p. 117-120
|
artikel
|
| 41 |
Tuberous sclerosis complex: A rare etiology of multiple subsolid nodules
|
Lantuéjoul, Lea
|
|
2019
|
134 |
C |
p. 268-271
|
artikel
|
| 42 |
UPSTAGING, CENTRALITY AND SURVIVAL IN EARLY STAGE NON-SMALL CELL LUNG CANCER VIDEO-ASSISTED SURGERY
|
Boada, M.
|
|
2019
|
134 |
C |
p. 254-258
|
artikel
|
| 43 |
Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands
|
van de Ven, M.
|
|
2019
|
134 |
C |
p. 34-41
|
artikel
|
Tijdschrift beschrijving